Includes acute disseminated encephalomyelitis, AFP, GBS and transverse myelitis; monitoring of case numbers where receipt of vaccination occurred in previous 6 weeks for reporting as potentially severe AEFI; GBS cases post-influenza A(H1N1)pdm09 vaccine contributed to a multinational study of influenza A(H1N1)pdm09 vaccine safety. This evidence concerns the gene AFP and Guillain-Barre syndrome.